A prospective clinical study published online in The Veterinary Journal on 14 October 2026 evaluates nanofibrillated cellulose as a urethral bulking agent in female dogs with acquired urethral sphincter mechanism incompetence (USMI).

The paper comes from Nina M.M. Peltokallio, Géraldine Bolen, Emilia Gordin, Jaan Lepajõe, Annick Hamaide, Outi M. Laitinen-Vapaavuori and Stéphanie Noël. The team designed the work as a prospective clinical study, the standard format for measuring how a treatment performs under real clinical conditions rather than in a retrospective chart review.

Why USMI matters at the exam table

Acquired urethral sphincter mechanism incompetence is a leading cause of urinary incontinence in adult spayed female dogs. Practitioners typically manage it with medical therapy first, and bulking agents enter the conversation when drugs fail or owners refuse daily medication.

Existing injectable bulking materials have variable durability, and repeat procedures are common. A cellulose-based alternative, if it holds its effect, would give general practitioners and surgeons another option to discuss with owners of affected bitches.

What the study actually tested

The investigators evaluated nanofibrillated cellulose, a plant-derived material, as the bulking agent injected around the urethra to increase outlet resistance. The study population consisted of female dogs diagnosed with acquired USMI, and the prospective design means the authors enrolled and followed those patients specifically for this evaluation.

The published abstract and full text carry the outcome data, including continence scores and follow-up intervals. This report, drawn from the publication record, confirms the study's existence, its design, its authors and its release date; readers should consult the full open text in The Veterinary Journal for the specific success rates and complication figures.

What changes for practitioners

For companion-animal practice, the relevance is direct. USMI cases appear regularly in general practice, and owners often weigh procedural cost against lifelong phenylpropanolamine dosing. A new bulking material with documented prospective evidence gives clinicians a firmer basis for that conversation.

The material is not a drug in the regulatory sense familiar to FDA CVM watchers; cellulose bulking agents fall under device-type pathways, and practitioners should verify the marketing status of any specific product in their own jurisdiction before offering it.

No food-animal or public-health implications arise from this work; the study population is entirely companion dogs.

Reading the evidence honestly

One prospective clinical study does not settle a question. It establishes that the material can be evaluated systematically in owned patients and reports the first structured results. Confirmation will require replication, longer follow-up and comparison against established bulking agents and medical therapy.

The Veterinary Journal published the paper online on 14 October 2026, and the full dataset sits behind that publication for clinicians who want the numbers before changing anything in their protocol.

Watch this space: if the results hold up in replication, nanofibrillated cellulose could reshape how practitioners sequence therapies for incontinent bitches.